Intrust Bank NA reduced its holdings in shares of BioTelemetry, Inc. (NASDAQ:BEAT) by 23.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,978 shares of the medical research company’s stock after selling 2,438 shares during the quarter. Intrust Bank NA’s holdings in BioTelemetry were worth $238,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Winslow Evans & Crocker Inc. purchased a new position in BioTelemetry during the 3rd quarter valued at about $109,000. First Dallas Securities Inc. purchased a new position in BioTelemetry during the 4th quarter valued at about $133,000. Piedmont Investment Advisors LLC purchased a new position in BioTelemetry during the 2nd quarter valued at about $207,000. UBS Asset Management Americas Inc. purchased a new position in BioTelemetry during the 2nd quarter valued at about $208,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in BioTelemetry during the 2nd quarter valued at about $212,000. Hedge funds and other institutional investors own 83.27% of the company’s stock.
Shares of BioTelemetry, Inc. (NASDAQ:BEAT) opened at $33.67 on Friday. BioTelemetry, Inc. has a 12 month low of $23.30 and a 12 month high of $39.20. The stock has a market cap of $1,080.00, a PE ratio of 25.70, a price-to-earnings-growth ratio of 1.48 and a beta of 0.67. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 0.75.
Several equities research analysts have issued reports on BEAT shares. BidaskClub raised shares of BioTelemetry from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 19th. Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a research note on Thursday, November 2nd. SunTrust Banks started coverage on shares of BioTelemetry in a research note on Monday, October 23rd. They set a “buy” rating and a $41.00 price target on the stock. Dougherty & Co reaffirmed a “buy” rating and set a $40.00 price target on shares of BioTelemetry in a research note on Wednesday, November 8th. Finally, Raymond James Financial started coverage on shares of BioTelemetry in a research note on Thursday, October 26th. They set an “outperform” rating and a $37.00 price target on the stock. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. BioTelemetry currently has an average rating of “Buy” and an average target price of $42.86.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.